baona/iStock via Getty Images
On Saturday April 5, Anavex (NASDAQ:AVXL) announced data from their open-label extension (OLE) trial in early Alzheimer's Disease (AD), which they presented at the "AD/PDTM 2025 Conference".
This OLE trial, named ATTENTION-AD, was a follow-on, open-label trial from their previously completed double-blind (DB), randomized, placebo-controlled phase
Analyst’s Disclosure:I/we have a beneficial short position in the shares of AVXL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
I hold Jan 2026 put option on AVXL.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
